ClinicalTrials.gg
CompletedNCT00293813Updated Jul 25, 2014Results posted

A Multicenter, Randomized Placebo Controlled Pilot MicroCT Study to Estimate the Effect of Treatment With Denosumab (AMG 162) and Alendronate Sodium in Postmenopausal Women With Low Bone Mineral Density

A Phase 2 interventional study of Alendronate and Denosumab in Postmenopausal Osteoporosis, sponsored by Amgen. Completed. Open to female participants aged 50 Years to 70 Years. Per ClinicalTrials.gov, last updated 2014-07-25.

Sponsored by Amgen · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
247
Allocation
Randomized
Ages
50 Years to 70 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 31 studies testing denosumab in Osteoporosis, Postmenopausal — 1 open to participants now, 3 under way, 2 of them phase 3. Denosumab · Osteoporosis, Postmenopausal.

Enrollment
18th of 31
247 · median 278
Started
2006
with 1 other
Phase 2
2 of 31
none open now
Registered
3rd of 31
by date
Lead sponsor
12 of 31
Amgen

Among the 31 studies testing denosumab in Osteoporosis, Postmenopausal, this one is the 18th largest by enrollment, is one of 2 that started in 2006, is one of 2 in phase 2, and was the 3rd registered.

Osteoporosis, Postmenopausal

334 studies on the registry are indexed under Osteoporosis, Postmenopausal; 28 are open to participants now.

Browse Osteoporosis, Postmenopausal studies →

Open to participants now

1 of the 31 studies testing denosumab in Osteoporosis, Postmenopausal is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About denosumab

Denosumab: first FDA approval 2010 (PROLIA), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 20 Osteoporosis, Postmenopausal studies recruiting now, 8 (40%) set no upper age limit and 8 (40%) stop at 75 or younger; 1 takes children under 18; 7 take healthy volunteers.

This study: 50 Years to 70 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies testing denosumab in Osteoporosis, Postmenopausal, or all of them as a file.
02

Study summary

This study is structured to estimate the effect of denosumab, compared to placebo and alendronate, on several bone parameters.

03

Conditions studied

  • Postmenopausal Osteoporosis

Keywords

  • Post Menopausal
  • Osteoporosis
  • MicroCT
  • Amgen
  • denosumab
  • Extreme CT
  • XCT
  • Fosamax
  • Alendronate
04

Who can participate

Ages eligible
50 Years to 70 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • , ambulatory women between 50 and 70 years old who are generally in good health.
  • Must have low bone mineral density and meet specific eligibility criteria.

Key Exclusion Criteria:

-Subjects must not currently be receiving any medication that affects bone metabolism or have an underlying condition that affects their ability to take alendronate or receive denosumab.

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
247 participants (actual)

Study arms

  • Placebo comparator
    3

    Placebo for denosumab and placebo for alendronate

    Drug: Placebo

  • Experimental
    1

    denosumab and placebo for alendronate

    Drug: Denosumab

  • Active comparator
    2

    Placebo for denosumab and alendronate

    Drug: Alendronate

Interventions

  • Alendronate 70 mg PO QW

  • denosumab 60 mg SC q 6 mos

  • DrugPlacebo

    Placebo for alendronate and placebo for denosumab

06

What researchers measure

Primary outcomes

  1. Cortical Thickness of Radius by XtremeCT Percent Change From Baseline at Month 12

    Cortical Thickness measured by XtremeCT.

    Time frame: 12 months

Secondary outcomes

  1. Cortical Thickness of Tibia by XtremeCT Percent Change From Baseline at Month 12

    Cortical Thickness measured by XtremeCT.

    Time frame: 12 months

07

Results

Posted Jan 27, 2010

Participant flow

Participant flow — Overall Study
MilestoneAlendronate 70 mg QWDenosumab 60 mg Q6MPlacebo
Started828382
Completed697474
Not completed1398
Withdrew: Physician decision010
Withdrew: Adverse event311
Withdrew: Withdrawal by subject744
Withdrew: Lost to follow-up323
Withdrew: Noncompliance010

Outcome measures

PrimaryCortical Thickness of Radius by XtremeCT Percent Change From Baseline at Month 12

Cortical Thickness measured by XtremeCT.

Time frame:
12 months
Reported as:
Least squares mean · Percent Change from Baseline
Cortical Thickness of Radius by XtremeCT Percent Change From Baseline at Month 12
Percent Change from BaselineAlendronate 70 mg QWDenosumab 60 mg Q6MPlacebo
Cortical Thickness of Radius by XtremeCT Percent Change From Baseline at Month 122.4 (1.2 to 3.5)3.4 (2.2 to 4.5)-.8 (-1.8 to .3)
Statistical analysis
  • Denosumab 60 mg Q6M vs Placebo · ANCOVA · Mean difference (final values): 4.1 · 95% CI 2.6 to 5.7
  • Alendronate 70 mg QW vs Denosumab 60 mg Q6M · ANCOVA · Mean difference (final values): 1 · 95% CI -.6 to 2.6
SecondaryCortical Thickness of Tibia by XtremeCT Percent Change From Baseline at Month 12

Cortical Thickness measured by XtremeCT.

Time frame:
12 months
Reported as:
Least squares mean · Percent Change from Baseline
Cortical Thickness of Tibia by XtremeCT Percent Change From Baseline at Month 12
Percent Change from BaselineAlendronate 70 mg QWDenosumab 60 mg Q6MPlacebo
Cortical Thickness of Tibia by XtremeCT Percent Change From Baseline at Month 124.9 (4 to 5.8)5.8 (5 to 6.7)1.4 (.6 to 2.3)

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo—5/83 (6%)78/83 (94%)
Alendronate 70 mg QW—5/81 (6.2%)77/81 (95.1%)
Denosumab 60 mg Q6M—2/83 (2.4%)76/83 (91.6%)
Most frequent serious events
Most frequent serious events
EventPlaceboAlendronate 70 mg QWDenosumab 60 mg Q6M
Breast cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/832/810/83
CholelithiasisHepatobiliary disorders2/830/810/83
Biliary colicHepatobiliary disorders0/831/810/83
Adenocarcinoma of the cervixNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/831/810/83
Loss of consciousnessNervous system disorders0/831/811/83
Cholecystitis acuteHepatobiliary disorders0/830/811/83
PneumoniaInfections and infestations1/830/810/83
HyperglycaemiaMetabolism and nutrition disorders0/830/811/83
AmnesiaNervous system disorders1/830/810/83
Confusional statePsychiatric disorders1/830/810/83
Most frequent other events
Showing 10 of 25
Most frequent other events
EventPlaceboAlendronate 70 mg QWDenosumab 60 mg Q6M
ConstipationGastrointestinal disorders12/8313/8115/83
InfluenzaInfections and infestations15/8310/8114/83
NasopharyngitisInfections and infestations14/838/8110/83
HeadacheNervous system disorders9/8312/816/83
BronchitisInfections and infestations11/8311/819/83
Abdominal pain upperGastrointestinal disorders8/8310/815/83
DiarrhoeaGastrointestinal disorders9/8310/813/83
Pain in extremityMusculoskeletal and connective tissue disorders10/8310/8110/83
ArthralgiaMusculoskeletal and connective tissue disorders8/838/8110/83
Back painMusculoskeletal and connective tissue disorders10/836/8110/83

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Alendronate 70 mg QWDenosumab 60 mg Q6MPlaceboTotal
Mean60.7 ± 5.260.3 ± 5.960.8 ± 5.260.6 ± 5.4
Sex: Female, Male
Sex: Female, Male(Participants)Alendronate 70 mg QWDenosumab 60 mg Q6MPlaceboTotal
Female828382247
Male0000
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Seeman E, Delmas PD, Hanley DA, Sellmeyer D, Cheung AM, Shane E, Kearns A, Thomas T, Boyd SK, Boutroy S, Bogado C, Majumdar S, Fan M, Libanati C, Zanchetta J. Microarchitectural deterioration of cortical and trabecular bone: differing effects of denosumab and alendronate. J Bone Miner Res. 2010 Aug;25(8):1886-94. doi: 10.1002/jbmr.81. PubMed 20222106 ↗
  • Zebaze RM, Libanati C, Austin M, Ghasem-Zadeh A, Hanley DA, Zanchetta JR, Thomas T, Boutroy S, Bogado CE, Bilezikian JP, Seeman E. Differing effects of denosumab and alendronate on cortical and trabecular bone. Bone. 2014 Feb;59:173-9. doi: 10.1016/j.bone.2013.11.016. Epub 2013 Nov 22. PubMed 24275677 ↗
  • Hu YJ, Chines A, Shi Y, Seeman E, Guo XE. The effect of denosumab and alendronate on trabecular plate and rod microstructure at the distal tibia and radius: A post-hoc HR-pQCT study. Bone. 2022 Jan;154:116187. doi: 10.1016/j.bone.2021.116187. Epub 2021 Sep 14. PubMed 34530172 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2006, a primary completion of Mar 2008 and a completion of Aug 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2010, 1 year 10 months after primary completion. A results delay was requested in Nov 2009.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 17, 2006
First posted
Feb 20, 2006
Start
May 2006
Primary completionActual
Mar 2008
CompletionActual
Aug 2008
Results delay requested
Nov 23, 2009
Results first posted
Jan 27, 2010
Last update
Jul 25, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 25, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00293813
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
Feb 20, 2006
Start date
May 2006
Primary completion
Mar 2008
Completion
Aug 2008
Results posted
Jan 27, 2010
Last update
Jul 25, 2014

Study contacts

MD
study director · Amgen
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Denosumab

Start the discussion